Applied DNA Sciences Given Outperform Rating at Zacks (APDN)
Applied DNA Sciences (NASDAQ:APDN)‘s stock had its “outperform” rating reaffirmed by Zacks in a report issued on Thursday. They currently have a $0.25 price objective on the stock. Zacks‘s price objective would suggest a potential upside of 135.85% from the stock’s previous close.
Zacks’ analyst wrote, “We are optimistic about the Company’s unique technology and two principle anti-counterfeiting and product authentication solutions: SigNature DNA and fiberTyping, which can be used in numerous industries. With an ever booming anti-counterfeiting business worldwide, along with its unique technology and broad range of product offering, the Company is well positioned to grow in the coming years. APDN reported record revenue for fiscal 3Q14 and first nine months of fiscal 2014. We expect to see further growth of revenue in fiscal 4Q14 and beyond. “
Applied DNA Sciences (NASDAQ:APDN) traded down 0.94% on Thursday, hitting $0.105. 1,976,828 shares of the company’s stock traded hands. Applied DNA Sciences has a one year low of $0.08 and a one year high of $0.19. The stock’s 50-day moving average is $0.11 and its 200-day moving average is $0.12. The company’s market cap is $86.9 million.
Applied DNA Sciences, Inc is a provider of botanical-deoxyribonucleic acid (NASDAQ:APDN) based security and authentication solutions that can help protect products, brands and property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.